西安市全球基金耐多药结核病项目实施两年效果分析
发布时间:2018-04-15 20:30
本文选题:结核 + 肺 ; 参考:《现代预防医学》2017年06期
【摘要】:目的分析西安市全球基金耐多药结核病项目实施效果,为今后制定耐多药结核病控制策略提供依据。方法对项目执行期间的报表、实验室登记本、患者病案和追访信息等进行分析。结果截至2014年6月底,共登记耐多药结核病可疑者554例,554例均进行痰培养,培养结果阳性356例(64.26%),对292例培养结果阳性者行药敏实验,共确诊101例耐多药结核病患者,其中新患者耐多药检出率16.18%,不同患者分类的耐多药检出率差异有统计学意义(χ~2=13.54,P0.01)。52例确诊患者纳入"项目",纳入率51.49%;项目组治疗成功率55.77%,非项目组治疗成功率22.45%,差异有统计学意义(χ~2=11.71,P0.01);项目组患者6月末痰涂片阴转率60.78%,痰培养阴转率54.90%,12月末痰涂片阴转率65.31%,痰培养阴转率63.27%。结论耐多药高危人群筛查策略、定点医院治疗和疾控中心管理的防治模式是可行和高效的,项目实施为西安市耐多药防治打下了基础,为今后的工作提供了指导和借鉴。
[Abstract]:Objective to analyze the effect of MDR-TB project in Xi'an Global Fund, and to provide evidence for formulating MDR-TB control strategy in the future.Methods the report form, laboratory register, patient's medical record and information of follow-up were analyzed.Results by the end of June 2014, 554 suspected cases of MDR-TB were treated with sputum culture, 356 cases were positive and 64.260.292 cases of MDR-TB were tested by drug sensitivity test, 101 cases of MDR-TB were diagnosed.The detection rate of multidrug resistance in new patients was 16.18. The difference of multidrug resistance rate among different patients was statistically significant (蠂 ~ 2 ~ 2 ~ (13.54)) (P < 0.01). 52 patients with definite diagnosis were included in "project", the inclusion rate was 51.49.The success rate of project group was 55.77 and that of non-project group was 22.45.The sputum smear negative conversion rate in the project group was 60.78 at the end of June, the sputum culture negative conversion rate was 54.90 and the sputum smear negative conversion rate was 65.31 at the end of December, and the sputum culture negative conversion rate was 63.27.Conclusion the screening strategy of multidrug resistance high risk population, the treatment mode of designated hospital and the management mode of CDC are feasible and efficient. The implementation of the project lays a foundation for the prevention and treatment of multidrug resistance in Xi'an, and provides guidance and reference for future work.
【作者单位】: 西安市疾病预防控制中心;
【基金】:国家自然科学基金项目资助(项目编号:81272490) 陕西省社会发展科技攻关项目资助(项目编号:2015SF092)
【分类号】:R52
【相似文献】
相关期刊论文 前10条
1 马伟路,罗智;耐药和耐多药结核病及其控制[J];临床肺科杂志;2000年01期
2 于维琴;耐多药结核病的处理[J];临床肺科杂志;2000年03期
3 曾国武;78例耐多药结核病临床分析[J];医学文选;2000年05期
4 何国钧;新世纪耐多药结核病分子生物学诊断的重要性[J];中华传染病杂志;2001年06期
5 肖成志,李群辉,李拯民,傅瑜;耐多药结核病的治疗[J];临床肺科杂志;2001年03期
6 全国结核病胸部疾病科研协作组;耐多药结核病治疗的研究方案[J];临床肺科杂志;2001年03期
7 C.Conover,R.Ridzon,S.Valway,L.Schoenstadt,J.McAuley,I.Onorato,W.Paul,an investigative team ,王海东;美沙酮治疗规程中耐多药结核病的暴发[J];结核与肺部疾病杂志(中文版);2001年02期
8 陆强,王枢传;耐多药结核病的研究进展[J];天津药学;2002年01期
9 李一耕;我国耐多药结核病研究的现状与思考[J];新医学;2003年11期
10 张立兴 ,屠德华;加强预防和合理治疗耐多药结核病[J];中国防痨杂志;2003年01期
相关会议论文 前10条
1 马s,
本文编号:1755659
本文链接:https://www.wllwen.com/yixuelunwen/chuanranbingxuelunwen/1755659.html
最近更新
教材专著